ASPH and posterior cortical atrophy: Another small-molecule inhibitor of aspartate β-hydroxylase (ASPH), PAN-301-1 vaccine against ASPH has been tested in a phase I clinical trial in PCa patients, indicating that ASPH is a promising target (Kanwal et al., 2020).